chr5-132370259-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 4P and 4B. PM1PM2BP4_Strong
The NM_003060.4(SLC22A5):āc.287G>Cā(p.Gly96Ala) variant causes a missense change. The variant allele was found at a frequency of 0.000193 in 1,587,786 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G96R) has been classified as Uncertain significance.
Frequency
Consequence
NM_003060.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC22A5 | NM_003060.4 | c.287G>C | p.Gly96Ala | missense_variant | 1/10 | ENST00000245407.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC22A5 | ENST00000245407.8 | c.287G>C | p.Gly96Ala | missense_variant | 1/10 | 1 | NM_003060.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000263 AC: 40AN: 152242Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000414 AC: 81AN: 195700Hom.: 0 AF XY: 0.000393 AC XY: 42AN XY: 106942
GnomAD4 exome AF: 0.000186 AC: 267AN: 1435544Hom.: 0 Cov.: 34 AF XY: 0.000192 AC XY: 137AN XY: 711692
GnomAD4 genome AF: 0.000263 AC: 40AN: 152242Hom.: 0 Cov.: 32 AF XY: 0.000242 AC XY: 18AN XY: 74374
ClinVar
Submissions by phenotype
Renal carnitine transport defect Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | in vitro;research | Giacomini Lab, University of California, San Francisco | Oct 03, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 15, 2021 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 10, 2023 | Variant summary: SLC22A5 c.287G>C (p.Gly96Ala) results in a non-conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00041 in 195700 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in SLC22A5 causing Systemic Primary Carnitine Deficiency (0.00041 vs 0.0046), allowing no conclusion about variant significance. c.287G>C has been reported in the literature as a non-informative genotype (second allele not specified and/or reported as an unclassified variant) in settings of newborn screening for systemic primary carnitine deficiency (example, Li_2010, Frigeni_2017) and as a non-informative heterozygous genotype in a patient with a known pathogenic variant in SCN1A supporting the diagnosis of an SCN1A-related epilepsy (Dravet syndrome) (Vasta_2012). These data do not allow any conclusion about variant significance. At least two publications report conflicting experimental evidence on Carnitine transport/uptake assays depending upon the cell lines utilized (example, Frigeni_2017, Koleske_2022). The most pronounced variant effect results in approximately 20% of normal transport activity in a CHO-cell based system whereas a fully functional Carnitine uptake activity in a HEK-293 cell based system (Koleske_2022). The following publications have been ascertained in the context of this evaluation (PMID: 28841266, 36343260, 20574985, 26828774, 22494076). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (LP, n=1; LB, n=1; VUS, n=3). Based on the conflicting lines of evidence outlined above, the variant was classified as uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2023 | SLC22A5: PM2, PS3:Supporting - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at